Literature DB >> 20132123

Benzodiazepines, methadone and buprenorphine: interactions and clinical management.

Nicholas Lintzeris1, Suzanne Nielsen.   

Abstract

Benzodiazepines (BZDs) are widely used by heroin users not in treatment, and by patients in methadone and buprenorphine (BPN) treatment. This review examines the epidemiology of BZD use by opioid users, and the range of harms that are associated with BZD use in this group, including the association of BZD use with opioid-related mortality. Preclinical and clinical data regarding pharmacokinetic and pharmacodynamic interactions between methadone, buprenorphine, and BZDs are reviewed. An overview of treatment approaches for managing BZD use in this population is presented, including strategies for minimizing abuse and addressing BZD dependence.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20132123     DOI： 10.1111/j.1521-0391.2009.00007.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN： 1055-0496


  38 in total

1.  Neonatal abstinence syndrome: use of clonazepam?

Authors:  C Henderson; C Karnack
Journal:  J Perinatol       Date:  2015-10       Impact factor: 2.521

2.  Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Authors:  Michael D Stein; Mitika Kanabar; Bradley J Anderson; Anna Lembke; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2016-06-16

3.  Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Alfonso Ang; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2014-06-28

4.  Opiate withdrawal syndrome in buprenorphine abusers admitted to a rehabilitation center in Tunisia.

Authors:  Ines Derbel; Asma Ghorbel; Férièle Messadi Akrout; Abdelmajid Zahaf
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

5.  The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Authors:  Ziva D Cooper; Kirk W Johnson; Martina Pavlicova; Andrew Glass; Suzanne K Vosburg; Maria A Sullivan; Jeanne M Manubay; Diana M Martinez; Jermaine D Jones; Phillip A Saccone; Sandra D Comer
Journal:  Addict Biol       Date:  2015-05-14       Impact factor: 4.280

6.  Perceived stress and substance use in methadone-maintained smokers.

Authors:  Ethan Moitra; Bradley J Anderson; Michael D Stein
Journal:  Drug Alcohol Depend       Date:  2013-08-26       Impact factor: 4.492

7.  Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Authors:  Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham
Journal:  J Behav Health Serv Res       Date:  2017-07       Impact factor: 1.505

8.  Benzodiazepines and alcohol are associated with cases of fatal buprenorphine poisoning.

Authors:  Margareeta Häkkinen; Terhi Launiainen; Erkki Vuori; Ilkka Ojanperä
Journal:  Eur J Clin Pharmacol       Date:  2011-09-17       Impact factor: 2.953

9.  Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.

Authors:  Tae Woo Park; Marc R Larochelle; Richard Saitz; Na Wang; Dana Bernson; Alexander Y Walley
Journal:  Addiction       Date:  2020-01-20       Impact factor: 6.526

10.  Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Authors:  Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese
Journal:  Drug Alcohol Depend       Date:  2013-05-18       Impact factor: 4.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.